News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Pediatric glioblastomas: A histopathological and molecular genetic study.


Posted on: 11/19/2008

Neuro Oncol. 2008 Nov 3; [Epub ahead of print] Related Articles, LinkOut

 
Pediatric glioblastomas: A histopathological and molecular genetic study.

Sarkar C, Suri V, Das P, Jain A, Sharma MC, Borkar SA, Suri A, Gupta D.

Professor, Department of Pathology, All India Institute of Medical Sciences, Mehrauli Road, Ansari Nagar (W), New Delhi-110029, India.

Glioblastoma multiforme (GBM) occurs rarely in children. Relatively few studies have been performed on molecular properties of pediatric GBMs. To evaluate the genetic alterations in pediatric GBM (age</=18 years) with special reference to p53, p16 and p27 protein expression; epidermal growth factor receptor (EGFR) alterations and phosphate and tensin homolog gene (PTEN) deletion. Thirty cases of childhood GBMs reported between January 2002 to June 2007 were selected and H&E stained slides reviewed. Immunohistochemical staining was performed for EGFR, p53, p16, p27 and MIB-1 labeling index. Fluorescence in situ hybridization (FISH) analysis was performed to evaluate for EGFR amplification and PTEN deletion. Histopathological features and MIB-1 labeling index were similar to adult GBMs. p53 protein expression was observed in 63%. Though EGFR protein over-expression was noted in 23% cases, corresponding amplification of the EGFR gene was rare (5.5%). Deletion of the PTEN gene was also equally rare (5.5%). One case showed polysomy (chromosomal gains) of chromosomes 7 & 10. Loss of p16 and p27 immunoexpression was observed in 68% and 54 % cases respectively. In pediatric de novo/primary GBMs, deletion of PTEN and EGFR amplification are rare, while p53 alterations are more frequent as compared to pimary adult GBMs. Frequency of loss of p16 and p27 immunoexpression is similar to their adult counterparts. This suggests that pediatric malignant gliomas are distinctly different from adult GBMs highlighting the need for identification of molecular targets that may be adopted for future novel therapeutic strategies.

PMID: 18981259 [PubMed - as supplied by publisher]


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740